-
-
About PMI
- Welcome to PMI Science
- PMI Science Booklet
- Our Scientists
- The Cube: PMI’s R&D Center
- PMI’s Global Network
- Facts and Figures
About PMIExplore PMI Science, where innovation meets harm reduction. Learn about our scientists, smoke-free research, and commitment to transparency in research.Read More -
Smoke-free approach
- Harm Reduction
- Absence of Combustion
- Nicotine
- Cigarette Tar
- Tobacco regulation
- Harmful Chemicals Measured
Smoke-free approachPMI offers smoke-free alternatives with the potential to reduce the risk of harm for adult smokers who do not quit. Learn about harm reduction, the role of nicotine, and the regulation of smoke-free products.Read More -
Research
- PMI’s studies on smoke-free products
- Our findings
-
PMI Publications Library
- Assessment of the Effects of Acute and Continuous Exposure to Tobacco Heating System 2.4 and Cigarette Smoke Total Particulate Matter on a Direct 2D Osteoblast/Osteoclast Coculture Model
- An In Vitro Systems Toxicology Assessment of Novel Electronic Vapor Device by Using Air–Liquid Interface Buccal, Bronchial, Small Airway, and Alveolar Culture Models
- Literature reviews
- Independent studies
- Investigator Initiated Studies
ResearchDiscover PMI's rigorous scientific approach to smoke-free products and product assessment. Dive into our research results, peer-reviewed publications, independent research, and expert reports.Read More -
Our Products
- Heated tobacco products
- E-cigarettes and vaping products
- Nicotine pouches
- Nicotine Salts Product
Our ProductsPMI believes that offering a range of smoke-free alternatives is essential to ensure individual smokers are able to find a smoke-free product that they can fully switch to.Read More -
News & Events
- Scientific Update magazine
- Open Science events
- News
- Conferences calendar
News & EventsExplore the latest insights and stay informed about upcoming events and conference presentations from PMI scientists.Read More - Contact Us
-
About PMI
Inflammation And Morphometric Changes In The Lungs Of Spontaneously Hypertensive Rats Following Cigarette Smoke Exposure
Vanscheeuwijck, P.; Meurrens, K.; Van Miert, E.; Friedrichs, B.; Weiler, H.
Exposure to cigarette mainstream smoke (MS) induces lung inflammation, a key factor in the development of emphysema. Previously we have reported that acute and subchronic inhalation exposure of rats to diluted MS induces changes in inflammatory mediators and greater numbers of neutrophils in bronchoalveolar lavage fluid (BALF) (Vanscheeuwijck et al., 2004; Vanscheeuwijck et al., 2005; Friedrichs et al., in press). Here we report on inflammation and morphometric changes in the lungs of spontaneously hypertensive rats (SHR) following subchronic exposure to MS. The SHR strain is known to be susceptible to cigarette smoke and particle-induced cardiopulmonary alterations (Gilmour et al., 2004) and has been shown to have increased concentrations of MIP-2 and increased numbers of inflammatory cells in BALF following cigarette smoke exposure (Smith et al., 2002). We investigated pulmonary inflammation (cytokines, chemokines, and free lung cells in BALF) and morphometric changes in the lungs.
An In Vitro Systems Toxicology Assessment of Novel Electronic Vapor Device by Using Air–Liquid Interface Buccal, Bronchial, Small Airway, and Alveolar Culture Models
Community-Reviewed Biological Network Models for Toxicology and Drug Discovery Applications
Verification Of Systems Biology Research In The Age Of Collaborative - Competition
Verification Of Systems Biology Research In The Age Of Collaborative- Competition
Verification Of Systems Biology Research In The Age Of Collaborative- Competition: Biological Network Models
Verification of systems biology research in the age of collaborative competition
PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization.
Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.